| Patient stratification in myelodysplastic syndromes: how a puzzle may become a map |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Therapy for lower-risk MDS |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Existing agents, novel agents, or transplantation for high-risk MDS |
|
Hematology. American Society of Hematology. Education Program |
Myelodysplastic Syndromes (MDS) |
| Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria |
|
Hematology. |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Switching patients with PNH from pegcetacoplan to iptacopan: a case series |
|
Hematology. |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Real-world clinical outcomes and treatment response in complement inhibitor experienced and naïve PNH patients prescribed pegcetacoplan in Europe and Canada |
|
Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Kinetics of Pre-Myelodysplastic Syndromes Blood Values Correlate with Disease Risk and Survival |
|
Hematological Oncology |
Myelodysplastic Syndromes (MDS) |
| Myelodysplastic syndromes with ring sideroblasts |
|
Hematological Oncology |
Myelodysplastic Syndromes (MDS) |
| Iptacopan monotherapy resulted in increased hemoglobin level in patients with PNH and hemoglobin ≥10 g/dL after anti-C5 therapy |
|
HemaSphere |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Childhood myelodysplastic syndromes: Is cytoreductive therapy useful before allogeneic hematopoietic stem cell transplantation? |
|
HemaSphere |
Myelodysplastic Syndromes (MDS) |
